EGRX News and Press, Eagle Pharmaceuticals Inc. From 11/04/22

Eagle Pharmaceuticals ( NASDAQ: EGRX ) is scheduled to announce Q3 earnings results on Monday, November 7th, before market open. The consensus EPS Estimate is $0.91 (+62.5% Y/Y) and the consensus Revenue Estimate is $62.08M (+55.8% Y/Y). Over the last 2 years, EGRX h...

WOODCLIFF LAKE, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 third quarter financial results on Monday, November 7, 2022, before the market ope...

WOODCLIFF LAKE, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company will host an Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel, at 8:00am ET...

Eagle Pharmaceuticals ( NASDAQ: EGRX ) filed an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) seeking clearance to start a trial of CAL02 for treating severe community-acquired bacterial pneumonia (SCABP). The IND filing...

-- Company plans to commence an adequately powered Phase 2 study with approximately 276 patients with severe community-acquired pneumonia at 120 sites worldwide with patient enrollment expected as early as the beginning of 2023 -- -- Interim results expected approximately one year after...

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Eagle Pharmaceuticals ( NASDAQ: EGRX ) and Enalare Therapeutics' ENA-001 to treat Apnea of Prematurity (AoP). AoP occurs when newborns, especially those born prematurely, stop breathing for sh...

-- ENA-001, with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease Designation for the treatment of Apnea of Prematurity by the FDA with eligibility for a priority review voucher -- -- The compound is also being develo...

Eagle Pharmaceuticals ( NASDAQ: EGRX ) said Enalare Therapeutics secured a contract for up to $50.3M from the Biomedical Advanced Research and Development Authority (BARDA) to develop an an intramuscular formulation of ENA-001 for patients experiencing&...

-- ENA-001, a new chemical entity with a unique mechanism of action, is being developed as an agnostic respiratory stimulant for use in multiple patient populations experiencing acute respiratory depression -- -- Development is under way of intramuscular formulation for treatment of c...

WOODCLIFF LAKE, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the...